Japan stock market week to Sept 15, 2008

21 September 2008

Tokyo lost further ground in the week to September 15 (four trading days only because the last was a national holiday in Japan). The Nikkei 225 dropped 3.3% to close at the 12,200 mark, after temporarily hitting a six-month low, while the Topix index fell 3.2%. US reports about the bailout of troubled mortgage companies somewhat eased Japanese investors' worries about the USA's financial industry. However, another report that major broker Lehman Brothers continued to record net losses in the June-August period amid its financial troubles came as negative news. A later report of a possible buy-out of Lehman by a big financial institution encouraged Tokyo to bounce back in the last trading day, but the subsequent news of the broker's collapse came while the market was closed. The pharmaceutical index was off 1.9%, yet outperformed the market.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight